Diferencia en calidad de vida en pacientes con rinitis alérgica con Beclometasona vs Furoato de Mometasona y Fluticasona
Barra lateral del artículo
Contenido principal del artículo
Resumen
Introducción: La rinitis alérgica es una condición común en gran parte de la población en general. Afecta aproximadamente al 32% de la población en general.
Materiales y métodos: Estudio prospectivo en cohorte con un diagnóstico clínico
de rinitis alérgica en el Hospital Universitario de La Samaritana; se evaluó el cuestionario ESPRINT-15 validado en español previo y 3 post-tratamiento con Beclometasona, Furoato de Mometasona y Fluticasona
Resultados: Se incluyeron 160 pacientes en el estudio. Previo al tratamiento, los pacientes tratados con Beclometasona y Mometasona no presentaban diferencia entre la puntuación global del cuestionario. Posterior al tratamiento, se evidenció que el grupo tratado con Furoato de Mometasona presentaba una reducción estadísticamente significativa en la severidad de síntomas (2.0 vs. 3.0, p<0.001), actividad (1.6 vs. 2.7, p<0.001), sueño (1.7 vs 2.9, p<0.001) y afectación psicológica (1.3 vs 2.7, p<0.001) con respecto al grupo tratado con Beclometasona. En general, el grupo tratado con Beclometasona documentó efectos adversos más severos con respecto a la Mometasona.
Conclusiones: La Mometasona demuestra ser más efectiva y con efectos adversos menos severos con respecto a la Beclometasona, para el tratamiento de la rinitis alérgica.
Palabras clave: Rinitis alérgica, corticoide nasal, calidad de vida
Descargas
Detalles del artículo
Este artículo es publicado por la Revista Acta de Otorrinolaringología & Cirugía de Cabeza y Cuello.
Este es un artículo de acceso abierto, distribuido bajo los términos de la LicenciaCreativeCommons Atribución-CompartirIgual 4.0 Internacional.( http://creativecommons.org/licenses/by-sa/4.0/), que permite el uso no comercial, distribución y reproducción en cualquier medio, siempre que la obra original sea debidamente citada.
eISSN: 2539-0856
ISSN: 0120-8411
Citas
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. doi:10.1111/j.1398-9995.2007.01620.x.
Dennis RJ, Caraballo L, García E, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12:17. doi:10.1186/1471-2466-12-17.
Mygind N, Andersson M. Topical glucocorticosteroids in rhinitis: clinical aspects. Acta Otolaryngol. 2006;126(10):1022–1029. doi:10.1080/00016480600672550.
Mullol J, Obando A, Pujols L, Alobid I. Corticosteroid treatment in chronic rhinosinusitis: the possibilities and the limits. Immunol Allergy Clin North Am. 2009;29(4):657–668. doi:10.1016/j.iac.2009.07.001.
Aït-Khaled N, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64(1):123–148. doi:10.1111/j.1398-9995.2008.01884.x.
Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40–47. doi:10.1016/j.jaci.2004.04.042.
Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1–84. doi:10.1016/j.jaci.2008.06.003.
Valero A, Baró E, Sastre J, et al. Reference values for facilitating the interpretation of the ESPRINT-15 questionnaire (Spanish version). J Investig Allergol Clin Immunol. 2009;19(5):396–403.
Martínez C, Sossa M, Lemos E. Cost-Effectiveness Analysis of Mometasone Furoate Versus Beclomethasone Dipropionate for the Treatment of Pediatric Allergic Rhinitis in Colombia. Adv Ther 2015; 32:254–269.
Berger W, Meltzer E. Intranasal spray medications for maintenance therapy of allergic rhinitis. Am J Rhinol Allergy 2015; 29: 273-282.
Berlucchi M, Pedruzzi B. Intranasal Mometasone Furoate for Treatment of Allergic Rhinitis. Clinical Medicine Insights: Therapeutics 2010:2 761–769
Yonezaki M, Akiyama K, Karaki M, Goto R, et. all. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx 2015.
Penagos M, Compalati M, Tarantini F, et.all. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008: 63: 1280–1291.
Meltzer E, Jacobs E, LaForce C, Kelle L, et.all. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 2012; 33:249 –257.
Farid R, Farid F, Ghaffari J, Jabbarri F. Evaluation of fluticasone nasal spray vs Beclometasona nasal spray in the treatment of allergic rhinitis. Iranian journal of allergy, asthma and inmunology. 2003; 2: 193- 196.
Jaruvongvanich V, Mongkolpathumrat P, Chantaphakul H, Klaewsongkram J. Extranasal symptoms of allergic rhinitis are difficult to treat and affect quality of life. 2015; 1-5.
Blaiss MS, Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergic asma proc. 2011 Nov-Dec;32(6):413-8.
Berger, W; Jacobs R; Amar N ; Sudeesh K, et all. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol 115 (2015) 130-136.
Crawford1 B, Stanford R, Wong A, Dalal A, Bayliss M. Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire. Patient Related Outcome Measures 2011:2 127–133.
Piotr K; Wojciech; J, Spencer K, Katarina Z. Comparative safety and efficacy of two formulations of mometasone nasal spray in adult seasonal allergic rhinitis. Allergy and asthma procedingns 2014, Volume 35, Number 4: 332-337(6).
Davies R, Nelson H. Once-Daily Mometasone Furoate Nasal Spray: Efficacy and Safety of a New Intranasal Glucocorticoid for Allergic Rhinitis. Clinical therapeutics. 1997; 19: 27-38.
Hebert JR, Nolop K, Lutsky B. Once daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active- and placebo-controlled study. Allergy.
;51:569-576.
Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for perennial allergic rhinitis patients. Ann Allergy Asthma Zmmunol. 1996:77:153-160.
Sharpe M, Jarvis B. Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma [published correction appears in Drugs. 2001;61:1325–1350.
Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf. 2000;23:11–33.
Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther. 1997;19:27–38; discussion 2–3.
Frieri M, Therattil J, Chavarria V, et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81:431–437.
Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22:1458– 1467.
Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol. 2003;90:416–421.
Austin RJ, Maschera B, Walker A, et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002; 20:1386–1392.